Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.

被引：0
|
作者：
Greenwald, M
Hawker, G
Cooper, C
Hughes, C
Mairon, N
Bonvoisin, B
Silverman, S
机构：
[1] Desert Med Adv, Palm Desert, CA USA
[2] Sunnybrook & Womens Coll Hosp, Toronto, ON, Canada
[3] Univ Southampton, MRC, Epidemiol Resource Ctr, Southampton SO9 5NH, Hants, England
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
    Recker, RR
    Luckey, M
    Stakkestad, JA
    Civitelli, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [2] Once-monthly oral ibandronate in postmenopausal osteoporosis: Mobile 2-year safety and tolerability analysis
    Felsenberg, D.
    Stone, M.
    Zikan, V.
    Hughes, C.
    Burdeska, A.
    Minic, B.
    Cooper, C.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S67 - S67
  • [3] Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
    Silverman, S
    Greenwald, M
    Hawker, G
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Reginster, JY
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S735 - S736
  • [4] Once-monthly oral ibandronate is at least as effective as daily oral ibandronate in postmenopausal osteoporosis: 2-year findings from MOBILE.
    McClung, MR
    Drezner, MK
    Reginster, JY
    Bolognese, M
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [5] Favorable safety profile of once-monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from mobile
    Nuti, R
    Stakkestad, JA
    Czerwinski, E
    Leigh, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    BONE, 2005, 36 : S418 - S419
  • [6] Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
    Reginster, JY
    Adami, S
    Lakatos, P
    Greenwald, M
    Stepan, JJ
    Silverman, SL
    Christiansen, C
    Rowell, L
    Mairon, N
    Bonvoisin, B
    Drezner, MK
    Emkey, R
    Felsenberg, D
    Cooper, C
    Delmas, PD
    Miller, PD
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (05) : 654 - 661
  • [7] Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile
    Stepan, J. J.
    Kendler, D.
    Sedarati, F.
    Burdeska, A.
    Hughes, C.
    Lorenc, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 429 - 429
  • [8] Once-monthly oral ibandronate - Effective treatment for postmenopausal osteoporosis (PMO): MOBILE 2-year results
    Miller, P
    Drezner, M
    Lewiecki, M
    Bolognese, M
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 803 - 803
  • [9] Once-monthly and daily oral ibandronate are similarly well tolerated in women with postmenopausal osteoporosis: 2-year results from mobile
    Luckey, M.
    Stepan, J.
    Kendler, D. L.
    Feldman, D.
    Lipschitz, S.
    Leigh, C.
    Burdeska, A.
    Hiltbrunner, V
    Morales-Torres, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S234
  • [10] Safety profile of once-monthly oral ibandronate: MOBILE 2-year results
    Bolognese, M
    Luckey, M
    Miller, P
    Civitelli, R
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 793 - 793
12345